Dec 06,2023

Dexcom G7 is now connected to the Tandem t:slim X2 Insulin Pump

DexCom announced the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects with the t:slim X2 insulin pump by Tandem Diabetes Care in the United States, marking the first AID integration with the Dexcom G7 CGM system. Tandem will email instructions to all in-warranty t:slim X2 users in the United States to offer the option to add the new feature free of charge via remote software update. Tandem t:slim X2 pumps pre-loaded with Dexcom G7 integration are now shipping to new customers. Starting on 6th of December, Dexcom G7 sensors compatible with the t:slim X2 pump are available through Durable Medical Equipment (DME) distributors, with pharmacy availability launching in early January 2024.

COLLABORATION PARTNERSHIP

#connected device

#cgm

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 07,2023

Beta Bionics Announces the Nationwide Launch of the iLet Bionic Pancreas with Dexcom G7 CGM System

Beta Bionics announced the nationwide launch of the iLet Bionic Pancreas automated insulin delivery system with the Dexcom G7 Continuous Glucose Monitoring (CGM) System planned for December 18, 2023. Beta Bionics’ flagship product, the iLet Bionic Pancreas, is an autonomous insulin delivery system that streamlines diabetes management and reduces the burden on patients and physicians. The only input required to get started is the user’s weight. When iLet users “GO BIONIC” with their diabetes management, there’s no carb counting or calculating insulin corrections throughout the day.D excom G7 features an all-in-one sensor and transmitter and a 30-minute warmup time when starting a new sensor. This iLet Bionic Pancreas firmware update will allow users to select Dexcom G7 or Dexcom G6 CGMs, or switch back and forth, depending on their supplies.

COLLABORATION PARTNERSHIP

#connected device

#closed loop

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2023

Stakeholder Insights on rtCGM in T2D Population Health Management

The article explores the evolving landscape of type 2 diabetes (T2D) management within population health, with a specific focus on the underutilized potential of continuous glucose monitoring (CGM) technology, particularly real-time CGM (rtCGM). Sponsored by Dexcom, Inc Medical Affairs, the leading payer and health system stakeholders emphasize recent evidence supporting the integration of rtCGM in T2D population health programs. Highlighting studies such as the MOBILE randomized controlled trial and a Kaiser Permanente Northern California retrospective analysis, the article underscores the benefits of rtCGM, including significant reductions in HbA1c levels and resource utilization. The article concludes by advocating for the incorporation of rtCGM into comprehensive T2D population health initiatives, acknowledging its positive impact on outcomes, resource utilization, and member satisfaction.

#cgm

View Analyst & Ambassador Comments
Go to original news
Dec 06,2023 TOP STORY

Berkeley launches Agile Metabolic Health and open platforms initiative

Experts at UC Berkeley and UC San Francisco have begun working to improve the treatment of diabetes and metabolic health using a first-of-its-kind open-source platform with broad societal benefits. The Agile Metabolic Health project is being launched by Berkeley’s College of Computing, Data Science, and Society to illustrate how open platforms can transform healthcare. The ability to acquire, analyze and share safely and securely health records and data from wearable devices in one place would enable doctors and others to better understand and treat patients. This initial project could help the more than 38 million Americans who are diagnosed with diabetes. But the college’s vision is much bigger. It aims to do much more than improve diabetes care. What the college is building in partnership with developers from Project Jupyter, the 2i2c organization and The Commons Project is a platform to revolutionize the entire health ecosystem. This HIPAA-compliant platform will bring together previously siloed data, enable the rapid adoption of third-party healthcare apps, and give physicians and patients real-time insights.

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Dec 04,2023

Artificial Pancreas Device Systems Market projected to reach USD 1,099.0 Million by 2030, growing at a CAGR of 18.7% during the forecast period of 2023-2030

The Global Artificial Pancreas Device Systems (APDS) Market was valued USD 331 Million in 2022 and projected to reach USD 1,099.0 Million by 2030, growing at a CAGR of 18.7% during the forecast period of 2023-2030, according tot he research publisher. An Artificial Pancreas Device System is an integrated medical system designed to automate and optimize the delivery of insulin to individuals with diabetes. This innovative technology aims to mimic the functions of the human pancreas by continuously monitoring blood glucose levels and adjusting insulin delivery in real-time.

#closed loop

View Analyst & Ambassador Comments
Go to original news
Dec 05,2023 TOP STORY

National Employer Selects Dario Cardiometabolic and GLP-1 Solutions to Improve Employee Health

DarioHealth announced a new contract to provide cardiometabolic and GLP-1 solutions to a national employer beginning in January 2024. The Employer, a national logistics company, selected Dario to deliver integrated support for employees living with diabetes, pre-diabetes, weight management and hypertension, while also providing a tailored experience for employees taking a GLP-1 medication. Members using a GLP-1 or other anti-obesity medication receive a personalized experience optimizing digital coaching and professional human support, including guidance from a Certified Diabetes Educator, to improve overall health. As part of their experience, members have access to Dario's Medication Cabinet, a digital tool to help members track medication adherence, along with tailored lifestyle change programs and tools to support sustainable behavior change.

PRODUCT

#coaching

#dtx

View Analyst & Ambassador Comments
Go to original news
Nov 30,2023

CGMs: A Game-Changer for Sports Nutrition, as Explained by Dr. Andrew Jagim of Mayo Clinic Health System

Nutrisense registered dietitian nutritionist Heather Davis talks with Dr. Andrew Jagim of Mayo Clinic Health System about how to find the best sports nutrition advice, the role of CGMs in athletic performance, and what exciting research projects are on his radar for the future. The interview explores the use of Continuous Glucose Monitors (CGMs) in athletes, acknowledging their potential benefits in optimizing feeding strategies and timing. Additionally, Dr. Jagim reflects on a study indicating the positive impact of regular consultations with sports dietitians on athletes' dietary habits. Future research plans include a monitoring study with a wrestling team, integrating biomarkers and CGMs, as well as initiatives supporting the unique nutritional needs of firefighters

#cgm

View Analyst & Ambassador Comments
Go to original news
Nov 30,2023

Digital Diabetes Management Market to Hit USD 22.47 Billion by 2030

The Digital Diabetes Management Market, as per the research publisher, was valued at approximately USD 12.053 billion in 2022, and it is projected to achieve a CAGR of 8.1% during the forecast period of 2023-2030, reaching an estimated size of USD 22.47 billion by 2030. The advent of artificial intelligence (AI) and machine learning in diabetes management has further bolstered the capabilities of these digital tools, enabling more accurate predictive analytics and personalized treatment plans.

#cgm

#insulin pen

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Nov 30,2023

Glucotrack Announces 180-Day Extension To Regain Compliance With Nasdaq Minimum Bid Price Requirement

Glucotrack, a medical device company focused on glucose monitoring technologies for people with diabetes and prediabetes, announced today it has received a notification letter from Nasdaq Stock Market that the Company has been granted an additional 180-day compliance period, or until May 20, 2024, to regain compliance with Nasdaq’s minimum bid price rule. In a notification letter dated May 26, 2023, Nasdaq informed the Company that, based on the previous 30 consecutive business days, the Company’s common stock no longer met the minimum $1.00 bid price per share requirement. Therefore, in accordance with Nasdaq’s Listing Rule, the Company was provided 180 calendar days, or until November 22, 2023, to regain compliance. On November 24, 2023, the Company received a letter from Nasdaq notifying the Company that it is eligible for an additional 180 calendar day period to regain compliance. If, at any time before May 20, 2024, the closing bid price of the Company’s common stock is at least $1.00 per share for a minimum of 10 consecutive business days, the Company will regain compliance with this Nasdaq rule.

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES